Krzys Misiukiewicz

Icahn School of Medicine at Mount Sinai

Papers

2

Total Citations

21

H-Index

2

About

Krzysztof "Krzys" Misiukiewicz is a leading oncologist and translational researcher whose work focuses on the intersection of immunotherapy and head and neck cancers, particularly human papillomavirus-associated oropharyngeal cancer (HPVOPC). His major contributions center on pioneering the use of live attenuated *Listeria monocytogenes*-based immunotherapy (ADXS11-001) to target HPV E7 antigens. In a landmark "window of opportunity" trial, Misiukiewicz demonstrated that administering this immunotherapy prior to robotic surgery in HPV-positive oropharyngeal cancer patients could enhance HPV-specific T cell immunity within the tumor microenvironment. His 2016 study, which has garnered 19 citations, provided critical early evidence that this approach is both feasible and immunologically active, paving the way for neoadjuvant immunotherapy strategies. By showing measurable changes in local and peripheral T cell diversity, his work has helped establish a foundation for leveraging viral antigens to turn immunologically "cold" tumors hot. Misiukiewicz’s research is instrumental in shifting treatment paradigms toward less toxic, immune-driven therapies for HPV-driven malignancies, offering new hope for patients with this rapidly rising cancer.

Research Focus

Key Achievements

2
H-Index
2
Papers
21
Total Citations
11
Avg Citations/Paper
🏆 Most Cited Paper
Abstract LB-095: HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer enhances HPV-specific T cell immunity
19 citations · 2016
📈 Most Prolific Year: 2016 (1 Papers)
🤝 Key Collaborators: 16
🏛 Institutions: Icahn School of Medicine at Mount Sinai

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago